PTEN and prostate cancer: Several inhibitors (rapamycin analogs) targeting the PI3K/AKT/mTOR pathway have been investigated to counteract the mechanism by which PTEN deletion promotes prostate cancer progression (60), but their antitumor effects have been disappointing.